Xilio Therapeutics (XLO) Treasury Shares (2020 - 2026)

Xilio Therapeutics has disclosed Treasury Shares across 7 years of filings, most recently posting $15914.0 for Q1 2026.

• Treasury Shares for Q1 2026 came in at $15914.0, down 95.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $15914.0 (down 95.24% YoY), and the FY2025 annual result was $23866.0, down 24.99% from the prior year.
• Treasury Shares came in at $15914.0 for Q1 2026 at Xilio Therapeutics, down from $23866.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $481500.0 in Q1 2024 to a low of $5617.0 in Q4 2023.
• The 5-year median for Treasury Shares is $64458.0 (2022), against an average of $164831.1.
• Across the five-year window, Treasury Shares jumped 3307.53% in 2024 and slumped 95.24% in 2026, its largest moves.
• Xilio Therapeutics' Treasury Shares stood at $46160.0 in 2022, then slumped by 87.83% to $5617.0 in 2023, then surged by 466.46% to $31818.0 in 2024, then slipped by 24.99% to $23866.0 in 2025, then tumbled by 33.32% to $15914.0 in 2026.
• The last three Treasury Shares figures came in at $15914.0 (Q1 2026), $23866.0 (Q4 2025), and $334125.0 (Q3 2025), per Business Quant data.